Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02395822 · ClinicalTrials.gov registry record · Phase 2
MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT02395822 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 17 participants.
The verdict
NCT02395822, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
A phase II trial of CD3/CD19 depleted, IL-15 activated, donor natural killer (NK) cells in adults and subcutaneous IL-15 given after a preparative regimen for the treatment of relapsed or refractory acute myelogenous leukemia (AML). The primary objective is to study the potential efficacy of NK cells and IL-15 to achieve complete remission while maintaining safety.
Interventions
- BIOLOGICAL IL-15
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2015-10-01 |
| Est. Completion | 2016-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02395822
The ClinicalTrials.gov registry entry for NCT02395822 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IL-15 is the first listed.
NCT02395822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02395822 about?
NCT02395822 is a clinical study titled "MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients". A phase II trial of CD3/CD19 depleted, IL-15 activated, donor natural killer (NK) cells in adults and subcutaneous IL-15 given after a preparative regimen for the treatment of relapsed or refractory acute myelogenous leukemia (AML). The primary objective is to study the potential efficacy of NK cell...
What is the current status of trial NCT02395822?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2015-10-01. Estimated completion is 2016-12-01.
What interventions are being tested in trial NCT02395822?
The interventions under investigation include: IL-15 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02395822?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.